The goal of this component of the POI application is to develop methods to evaluate the relative abuse liability of tobacco products in animals. The tobacco industry is introducing several "modified risk" tobacco products (MRTPs) promoted to be safer or less addictive than conventional products. The Food and Drug Administration (FDA) is now required to evaluate the abuse liability of current and future MRTPs. Animal models are urgently needed for this process because they allow a) examination of critical phenomena that cannot be studied experimentally in humans (e.g., initiation of tobacco use in adolescents), b) isolation of the role of nicotine and other tobacco constituents from other factors, and c) screening of novel tobacco formulations prior to human exposure. Current animal models that only examine nicotine or other isolated constituents may not accurately assess the abuse liability of tobacco products because a) as yet unidentified compounds may contribute (positively or negatively) to tobacco abuse and b) it is the interaction of these compounds that determines the actual abuse liability of a product. The current project will address this issue by using well-established animal models to examine the abuse liability of aqueous tobacco extracts from four different MRTPs and a conventional product. These extracts provide an extensive range of nicotine and other tobacco constituents to more closely model actual product exposure in humans.
Aim la will compare the reinforcing efficacy of tobacco extracts and nicotine with intravenous self-administration (SA) models using behavioral economic methods Aim 1b will compare acquisition of extract and nicotine SA in adolescent and adult rats.
Aim 1 c will compare extracts and nicotine in terms of their reinforcement-enhancing and aversive effects measured as changes in intracranial self-stimulation (ICSS) thresholds.
Aim 2 will compare the ability of chronic infusion of extracts and nicotine to induce dependence as measured by withdrawal-induced elevations in ICSS thresholds. Because some non-nicotine constituents are known to enhance nicotine's dependence-related effects, the general working hypothesis is that tobacco extracts will have greater abuse liability than equivalent doses of pure nicotine. We also hypothesize that the proposed methods will be sufficiently sensitive to distinguish between extracts of different products. The proposed studies were specifically designed to parallel the human studies in this POI by a) employing behavioral economic methods to assess reinforcing efficacy, b) measuring withdrawal severity, and c) examining some of the same products. As such, this POI will allow validation of behavioral economics as a framework for integrating findings across species and predicting population-level abuse of different products. Examining abuse liability in adolescents will provide a critical extension of the human projects. By studying several more products than the human studies, findings in animals may help prioritize other products that need to be evaluated in humans. This study will provide the basis for standardized animal models of abuse liability to evaluate tobacco products and inform FDA regulation of performance standards.

Public Health Relevance

The FDA is now required to evaluate and regulate tobacco products toward the goal of protecting public health. This study will develop animal models to assess the relative abuse liability of several tobacco products using aqueous extracts of those products that provide a range of constituents similar to product exposure in humans. In concert with humans studies in this POI, these models may be useful for anticipating the likelihood and extent of population-level abuse of new tobacco products in humans and its associated impact on public health. They may also help understand how chemicals other than nicotine contribute to tobacco addiction and suggest relevant performance standards for tobacco products to limit or reduce their addictiveness.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19CA157345-03
Application #
8728610
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
3
Fiscal Year
2014
Total Cost
$299,465
Indirect Cost
$57,132
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Bickel, Warren K; Johnson, Matthew W; Koffarnus, Mikhail N et al. (2014) The behavioral economics of substance use disorders: reinforcement pathologies and their repair. Annu Rev Clin Psychol 10:641-77
Ho, Yen-Yi; Baechler, Emily C; Ortmann, Ward et al. (2014) Using gene expression to improve the power of genome-wide association analysis. Hum Hered 78:94-103
Vogel, Rachel Isaksson; Hertsgaard, Louise A; Dermody, Sarah S et al. (2014) Sex differences in response to reduced nicotine content cigarettes. Addict Behav 39:1197-204
Bickel, Warren K; Koffarnus, Mikhail N; Moody, Lara et al. (2014) The behavioral- and neuro-economic process of temporal discounting: A candidate behavioral marker of addiction. Neuropharmacology 76 Pt B:518-27